Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reissue Patent
2006-09-19
2006-09-19
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S216000, C514S223500, C514S224500, C514S225500, C514S231200, C514S282000, C514S304000, C514S305000, C514S306000, C514S307000, C514S812000
Reissue Patent
active
RE039300
ABSTRACT:
Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.
REFERENCES:
patent: 2770569 (1956-11-01), Fromherz et al.
patent: 4126684 (1978-11-01), Robson et al.
patent: 4316888 (1982-02-01), Nelson
patent: 4362870 (1982-12-01), Portoghese
patent: 4416871 (1983-11-01), Walter et al.
patent: 4446140 (1984-05-01), Nelson
patent: 4464378 (1984-08-01), Hussain
patent: 4476141 (1984-10-01), Cormier
patent: 4602909 (1986-07-01), Csillik
patent: 4758559 (1988-07-01), Wasley
patent: 4769372 (1988-09-01), Kreek
patent: 4785000 (1988-11-01), Kreek et al.
patent: 4788055 (1988-11-01), Fischer et al.
patent: 4806543 (1989-02-01), Choi
patent: 4816264 (1989-03-01), Phillips
patent: 4816450 (1989-03-01), Bell et al.
patent: 4828836 (1989-05-01), Elger et al.
patent: 4834965 (1989-05-01), Martani et al.
patent: 4834985 (1989-05-01), Elger et al.
patent: 4876276 (1989-10-01), Mechoulam et al.
patent: 4888347 (1989-12-01), Woodruff et al.
patent: 4906779 (1990-03-01), Weber et al.
patent: 4912114 (1990-03-01), Revesz
patent: 4919916 (1990-04-01), Golwyn
patent: 4924008 (1990-05-01), Abou-Gharbia et al.
patent: 4937232 (1990-06-01), Bell et al.
patent: 4942182 (1990-07-01), Weiss et al.
patent: 4959493 (1990-09-01), Ohfume et al.
patent: 4975430 (1990-12-01), Jahr et al.
patent: 4990519 (1991-02-01), Jones et al.
patent: 4994446 (1991-02-01), Sokolovsky et al.
patent: 4994467 (1991-02-01), Zimmerman
patent: 4996047 (1991-02-01), Kelleher
patent: 5006510 (1991-04-01), Ellis
patent: 5013540 (1991-05-01), Redburn
patent: 5023239 (1991-06-01), Ogura et al.
patent: 5028611 (1991-07-01), Halikas
patent: 5028707 (1991-07-01), Nichols et al.
patent: 5034395 (1991-07-01), Tamada et al.
patent: 5034400 (1991-07-01), Olney
patent: 5041446 (1991-08-01), Silvestrini
patent: 5047229 (1991-09-01), Nahas et al.
patent: 5051426 (1991-09-01), Parnell
patent: 5051442 (1991-09-01), Saliturio et al.
patent: 5055481 (1991-10-01), Inukai et al.
patent: 5057519 (1991-10-01), Suberg
patent: 5068228 (1991-11-01), Kohler
patent: 5071646 (1991-12-01), Malkowska
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5091391 (1992-02-01), Aizenman et al.
patent: 5093129 (1992-03-01), Horovitz et al.
patent: 5093525 (1992-03-01), Weber et al.
patent: 5095009 (1992-03-01), Whitten et al.
patent: 5106847 (1992-04-01), Salituro et al.
patent: 5109017 (1992-04-01), Schmiesing et al.
patent: 5118675 (1992-06-01), Jirovsky et al.
patent: 5124319 (1992-06-01), Baudy et al.
patent: 5124340 (1992-06-01), Jaffe et al.
patent: 5126330 (1992-06-01), Ogura et al.
patent: 5133974 (1992-07-01), Paradissis
patent: 5137889 (1992-08-01), Tamada et al.
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5141957 (1992-08-01), Jiang et al.
patent: 5145842 (1992-09-01), Driedger et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5166207 (1992-11-01), Smith
patent: 5171752 (1992-12-01), Caldirola et al.
patent: 5183807 (1993-02-01), della Valle et al.
patent: 5185329 (1993-02-01), Gawin et al.
patent: 5190925 (1993-03-01), dalla Valle et al.
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5352683 (1994-10-01), Mayer et al.
patent: 5441982 (1995-08-01), Itzhak
patent: 5654281 (1997-08-01), Mayer et al.
Pharmacol. Biochem. Behav. vol. 35, No. 4 (1990), pp. 829-832.
Pharmacol. Biochem. Behav. vol. 43, No. 2 (1992), pp. 487-490.
Disch. Apoth.-Zig. vol. 119, No. 21 (1979), p. 821, “Opiat-Rezeptoren und Endorphine”.
Truillo et al.; “Inhibition of Morphine . . . MIC801”; Science; vol. 251, pp. 84-87.
Marek et al; “Brain Research, Delayed application of MIC801 . . . in rats.”; vol. 558, pp. 163-165.
Adams et al., “Emergency Intravenous Sedation of the Delirious, Medically Ill Patient,”J. Clin. Psychiatry, 49:12 Suppl., pp. 23-27 (1988).
Ben-Eliyahu et al., “The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat,”Brain Research, vol. 575, pp. 304-308 (1991).
Bristow et al., “Subcutaneous ketamine analgesia: postoperative analgesia using subcutaneous infusions of ketamine and morphine,”Annals of the Royal College of Surgeons of England, vol. 71 (1989).
Chapman et al., “The Combination of NMDA Antagonism and Morphine Produces Profound Antinociception in the Rat Dorsal Horn,”Brain Research, vol. 573, pp. 321-323 (1991).
Dickenson et al., “Dextromethorphan and Levorphanol on Dorsal Horn Nociceptive Neurones in the Rat,”Neuropharmacology, vol. 30, No. 12A, pp. 1303-1308 (1991).
Haley et al., “Evidence for spinal N-Methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat,”Brain Research, vol. 518, pp. 218-226 (1989).
Hayes et al., “Pretreatment with gangliosides reduces abnormal nociceptive responses associated with a rodent peripheral mononeuropathy,”Pain, vol. 48, pp. 391-396 (1992).
Itzhak et al. “Sensitization to the Toxic Effects of Cocaine in Mice is Associated with the Regulation of N-Methyl-D-Aspartate Receptors in the Cortex”,The Journal of Pharmacology and Experimental Therapeutics, vol. 262, No. 2, pp. 464-470 (1992).
Kamei et al., “Subsensitivity to the Cough-Depressant Effects of Opioid and Nonopiod Antitussives in Morphine-Dependent Rats: Relationship to Central Serotonin Function,”Pharmacology Biochemistry&Behavior, vol. 34, pp. 595-598 (1988).
Kanamaru et al., “Ketamine infusion for Control of Pain in Patients with Advanced Cancer,” pp. 1368-1371 (1990) (see English translation of abstact).
Koyunchoglu et al., “The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with Chlorpromazine,”International Journal of clinical Pharmacology, Therapy and Toxicology, vol. 28, No. 4 pp. 147-152 (1990).
Koyuncuoglu et al., “Previous Chronic Blockade of NMDA Receptors Intensifies Morphine Dependence in Rats,”Pharmacology Biochemistry&Behavior, vol. 39, pp. 575-579 (1991).
Koyuncuoglu et al., “Suppression by Ketamine and Dextromethorphan of Precipitated Abstinence Syndrome in Rats”,Pharmacology Biochemistry and Behavior, vol. 35, No. 4, pp. 829-832 (1990).
Koyuncuoglu et al., “Effects of MK 801 on Morphine Physical Dependence: Attenuation and Intensification,”Pharmacology Biochemistry&Behavior, vol. 43, pp. 487-490 (1992).
Mao et al., “Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy,”Brain Research, vol. 576, pp. 254-262 (1992).
Mao et al., “Post-injury treatent with GM1 ganglioside reduces nociceptive behaviors and spinal cord metabolic activity in rats with experimental peripheral mononeuropathy,”Brain Research, vol. 584, pp. 18-27 (1992).
Mao et al., “Intrathecal GM1 ganglioside and local ganglioside and local nerve anesthesia reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy,”Brain Research, vol. 584, pp. 28-35 (1992).
Mao et al., “Pain-related increases in spinal cord membrane-bound protein kinase C following peripheral nerve injury,”Brain Research, vol. 588, pp. 144-149 (1992).
Marek et al., “Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat”,Brain Research, vol. 547, pp. 77-81 (1991).
Marek et al., “Delayed application of MK-801 attenuates development of morphine tolerance in rats,”Brain Research, vol. 558, pp. 163-165 (1991).
Mankowitz et al., “
Mao Jianren
Mayer David J.
Virginia Commonwealth University Medical College of Virginia
Wang Shengjun
LandOfFree
Inhibiting the development of tolerance to and/or dependence... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibiting the development of tolerance to and/or dependence..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibiting the development of tolerance to and/or dependence... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536416